review Open AccessTop 1% cited
Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
Annals of Oncology · 2015 · Vol. 27(4) · pp. 559–574
Stéphane Champiat(Université Paris-Sud)Olivier Lambotte(Université Paris-Sud)Emmanuel Barreau(Bicêtre Hospital)Rakiba Belkhir(Assistance Publique – Hôpitaux de Paris)A. Berdelou(Université Paris-Sud)Franck Carbonnel(Université Paris-Sud)Cécile Cauquil(Bicêtre Hospital)P. Chanson(Inserm)Michael Collins(Université Paris-Sud)Antoine Dürrbach(Inserm)Stéphane Éderhy(Sorbonne Université)S. Feuillet(Université Paris-Saclay)Arnaud François(Inserm)Julien Lazarovici(Université Paris-Sud)Jérôme Le Pavec(Université Paris-Sud)Eléonora De Martin(Inserm)Christine Mateus(Université Paris-Sud)Jean‐Marie Michot(Institut Gustave Roussy)Didier Samuel(Inserm)Jean‐Charles Soria(Université Paris-Sud)Caroline Robert(Université Paris-Sud)Alexander M.M. Eggermont(Institut Gustave Roussy)Aurélien Marabelle✉(Université Paris-Sud)
Cancer Immunotherapy and BiomarkersCAR-T cell therapy researchLung Cancer Treatments and MutationsMedicineBlockadeImmune checkpointOncologyImmunotherapyNivolumabAdverse effectInternal medicineMelanomaImmune system
MeSH terms
Antibodies, MonoclonalCarcinoma, Non-Small-Cell LungHumansImmunotherapyMelanomaDisease ManagementCTLA-4 AntigenProgrammed Cell Death 1 ReceptorDrug-Related Side Effects and Adverse Reactions
Citations
885
FWCI
37.07
field-weighted impact
References
87
Percentile
100%
vs. same field & year
Citations per year
Cited by
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Journal of Clinical Oncology · 2018 · 3,616 citations
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Annals of Oncology · 2017 · 2,321 citations
References
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
New England Journal of Medicine · 2015 · 9,308 citations
Immune Reconstitution Inflammatory Syndrome
Medicine · 2002 · 647 citations
Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Journal of Clinical Oncology · 2010 · 2,913 citations
A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C
Journal of Hepatology · 2013 · 982 citations
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Clinical Cancer Research · 2009 · 3,204 citations
T cell exhaustion
Nature Immunology · 2011 · 3,925 citations
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
New England Journal of Medicine · 2015 · 8,491 citations
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
New England Journal of Medicine · 2012 · 12,531 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.